Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment
Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the ...
Hosted on MSN20d
J&J’s fully subcutaneous Tremfya shows 27.6% clinical remission in UC
Tremfya is a fully human antibody created to neutralise inflammation by blocking IL-23, a cytokine that plays a part in autoimmune and inflammatory diseases. It is currently approved in the US for ...
Yahoo Finance19d
Review and Outlook of Sanyou Bio Intelligent Super-trillion Molecule Discovery Platform
These include super-trillion fully human antibody discovery platform, super-trillion common light chain antibody discovery platform, super-trillion 2C type single-domain antibody discovery ...